{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:05:50Z","timestamp":1793217950244,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtha.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:28:36Z","timestamp":1725618516000},"page":"3500-3509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6548-0367","authenticated-orcid":false,"given":"Paul","family":"Dobry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.08.009_bib1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for vte disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.08.009_bib2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.08.009_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2024.08.009_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.08.009_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15386\/mpr-1372","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu","year":"2020","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.jtha.2024.08.009_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14779072.2019.1581064","article-title":"Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management","volume":"17","author":"Pouwels","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jtha.2024.08.009_bib7","author":"Stierman"},{"key":"10.1016\/j.jtha.2024.08.009_bib8","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.009_bib9","first-page":"109","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"83","author":"Writing Committee Members","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.08.009_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00228-024-03672-y","article-title":"Factor Xa inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation","volume":"80","author":"Dobry","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.08.009_bib11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/10600280221089008","article-title":"Management of venous thromboembolism in morbid obesity with rivaroxaban or warfarin","volume":"56","author":"Weaver","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2024.08.009_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/phar.2655","article-title":"Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity","volume":"42","author":"Crouch","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2024.08.009_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11239-023-02774-1","article-title":"DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network","volume":"55","author":"Martin","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.08.009_bib14","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.08.009_bib15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2024.08.009_bib16","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","article-title":"The \u201cobesity paradox\u201d in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial","volume":"37","author":"Sandhu","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2024.08.009_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.009_bib18","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2024.08.009_bib19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.009_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40256-022-00524-x","article-title":"Apixaban use in obese patients: a review of the pharmacokinetic, interventional, and observational study data","volume":"22","author":"Jamieson","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jtha.2024.08.009_bib21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40262-022-01160-z","article-title":"Rivaroxaban pharmacokinetics in obese subjects: a systematic review","volume":"61","author":"Alalawneh","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.08.009_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.009_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.009_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.009_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:18:16Z","timestamp":1764559096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1538783624004951"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.08.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}